Eliana Merle
Stock Analyst at Barclays
(3.92)
# 1,817
Out of 4,476 analysts
364
Total ratings
50%
Success rate
5.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $527 | $312.78 | +68.49% | 13 | Jun 29, 2026 | |
| MRNA Moderna | Maintained: Hold | $48 | $79.76 | -39.82% | 29 | Jun 29, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $115 | $81.80 | +40.59% | 19 | Jun 26, 2026 | |
| SABS SAB Biotherapeutics | Initiated Coverage: Buy | $13 | $3.92 | +231.63% | 1 | Jun 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $615 | $528.04 | +16.47% | 13 | Jun 22, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Hold | $20 | $19.28 | +3.73% | 11 | Jun 22, 2026 | |
| QURE uniQure | Upgraded: Buy | $65 | $41.81 | +55.47% | 12 | Jun 22, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $133 | $113.51 | +17.17% | 11 | Jun 22, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $70 | $57.80 | +21.11% | 5 | Jun 15, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $157 | $77.19 | +103.39% | 18 | Jun 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $3.91 | +360.36% | 4 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $59 | $30.62 | +92.68% | 8 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $237 | $111.60 | +112.37% | 5 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $83.31 | +44.04% | 10 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $105 | $58.99 | +78.00% | 39 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $917 | $654.27 | +40.16% | 3 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $0.3 → $0.28 | $0.1732 | +61.66% | 13 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $12 | $13.28 | -9.64% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $3.16 | +532.91% | 6 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $342 → $345 | $274.50 | +25.68% | 11 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $964 | $528.10 | +82.54% | 13 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $43 | $33.47 | +28.47% | 5 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 | $7.61 | +5.12% | 4 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 | $13.00 | +153.85% | 1 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $115 → $117 | $97.55 | +19.94% | 25 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $33 → $20 | $63.42 | -68.46% | 25 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $96 → $112 | $131.27 | -14.68% | 3 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 → $12 | $83.99 | -85.71% | 3 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.03 | +294.09% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $74 → $21 | $8.39 | n/a | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $2.2 | $4.46 | n/a | 6 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 | $189.24 | n/a | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $5 | $38.54 | n/a | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $22 | $24.21 | n/a | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $10.59 | n/a | 3 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $192 → $134 | $30.39 | n/a | 10 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $1.81 | n/a | 8 | Dec 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $4.19 | n/a | 4 | Mar 18, 2019 |
Alnylam Pharmaceuticals
Jun 29, 2026
Maintained: Buy
Price Target: $527
Current: $312.78
Upside: +68.49%
Moderna
Jun 29, 2026
Maintained: Hold
Price Target: $48
Current: $79.76
Upside: -39.82%
Ionis Pharmaceuticals
Jun 26, 2026
Maintained: Buy
Price Target: $115
Current: $81.80
Upside: +40.59%
SAB Biotherapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $3.92
Upside: +231.63%
Vertex Pharmaceuticals
Jun 22, 2026
Maintained: Buy
Price Target: $615
Current: $528.04
Upside: +16.47%
Sarepta Therapeutics
Jun 22, 2026
Maintained: Hold
Price Target: $20
Current: $19.28
Upside: +3.73%
uniQure
Jun 22, 2026
Upgraded: Buy
Price Target: $65
Current: $41.81
Upside: +55.47%
Kymera Therapeutics
Jun 22, 2026
Maintained: Buy
Price Target: $133
Current: $113.51
Upside: +17.17%
MBX Biosciences
Jun 15, 2026
Maintained: Buy
Price Target: $70
Current: $57.80
Upside: +21.11%
BridgeBio Pharma
Jun 5, 2026
Maintained: Buy
Price Target: $157
Current: $77.19
Upside: +103.39%
Jun 4, 2026
Maintained: Buy
Price Target: $18
Current: $3.91
Upside: +360.36%
Jun 3, 2026
Maintained: Buy
Price Target: $59
Current: $30.62
Upside: +92.68%
May 28, 2026
Maintained: Buy
Price Target: $237
Current: $111.60
Upside: +112.37%
May 27, 2026
Reiterated: Buy
Price Target: $120
Current: $83.31
Upside: +44.04%
May 21, 2026
Rated: Buy
Price Target: $105
Current: $58.99
Upside: +78.00%
May 18, 2026
Maintained: Buy
Price Target: $917
Current: $654.27
Upside: +40.16%
May 18, 2026
Maintained: Sell
Price Target: $0.3 → $0.28
Current: $0.1732
Upside: +61.66%
May 15, 2026
Maintained: Buy
Price Target: $37 → $12
Current: $13.28
Upside: -9.64%
May 14, 2026
Maintained: Buy
Price Target: $20
Current: $3.16
Upside: +532.91%
May 11, 2026
Rated: Buy
Price Target: $342 → $345
Current: $274.50
Upside: +25.68%
May 8, 2026
Rated: Buy
Price Target: $964
Current: $528.10
Upside: +82.54%
May 6, 2026
Maintained: Buy
Price Target: $43
Current: $33.47
Upside: +28.47%
Apr 2, 2026
Maintained: Hold
Price Target: $8
Current: $7.61
Upside: +5.12%
Jan 27, 2026
Maintained: Buy
Price Target: $33
Current: $13.00
Upside: +153.85%
Nov 6, 2025
Maintained: Hold
Price Target: $115 → $117
Current: $97.55
Upside: +19.94%
Aug 12, 2025
Maintained: Hold
Price Target: $33 → $20
Current: $63.42
Upside: -68.46%
Aug 8, 2025
Maintained: Hold
Price Target: $96 → $112
Current: $131.27
Upside: -14.68%
Jul 21, 2025
Downgraded: Hold
Price Target: $63 → $12
Current: $83.99
Upside: -85.71%
Jul 15, 2025
Maintained: Buy
Price Target: $8
Current: $2.03
Upside: +294.09%
May 15, 2025
Maintained: Buy
Price Target: $74 → $21
Current: $8.39
Upside: n/a
Jan 28, 2025
Maintained: Hold
Price Target: $5 → $2.2
Current: $4.46
Upside: n/a
Jan 8, 2025
Maintained: Buy
Price Target: $71
Current: $189.24
Upside: n/a
Apr 4, 2024
Maintained: Hold
Price Target: $3 → $5
Current: $38.54
Upside: n/a
Oct 13, 2022
Initiated Coverage: Buy
Price Target: $22
Current: $24.21
Upside: n/a
Mar 3, 2021
Reiterated: Buy
Price Target: $10
Current: $10.59
Upside: n/a
Aug 19, 2020
Maintained: Hold
Price Target: $192 → $134
Current: $30.39
Upside: n/a
Dec 11, 2019
Maintained: Buy
Price Target: $40
Current: $1.81
Upside: n/a
Mar 18, 2019
Reiterated: Buy
Price Target: $8
Current: $4.19
Upside: n/a